Elements

Slider

When it comes

to R&D, We’re #1!

Find Out MoreWatch video

50th

Anniversary

Find Out MoreWatch video

New Drug

Announced!

Find Out MoreWatch video

Pricing Table

Revitrox

$ 99
  • Considering just how serious the medical issue of hepatitis is, we’ve made sure to invent the drug that deals with this health hazard in the quickest and most efficient way!
get started

Renalgin

$ 99
  • Because of just how serious the medical issue of hyperventilation is, we’ve made sure to invent the drug that deals with this health hazard in the quickest and most efficient way!
get started

Testimonials

I have been taking 100 mg bid for over a year now. I have never been so normal feeling in my gut. I do have some bad days with it, just depends on what I eat. I get stuck gas sometimes and have to really push and typically take a phazyme too…

Dr. Steven Moffat

Today was my first day on Revitrox. I was prescribed two 100 mg pills a day. So far it has been okay. I decided to be risky and really test it and have an iced coffee and Taco Bell. Usually I would be headed straight to the bathroom before I even finished my…

Dr. Mary Winker

I have had IBSD for 37 years which has made it impossible to hold down a job for long periods of time. I get a job and work as long as possible when they get tired of a sick employee then I have to look for another. Today is my first day of taking 100…

Dr. John Wallace

Call to action

With thousands of Research & Development

projects underway every year, we are doing everything humanly possible to make the world healthy again!

Read More

Images

Animated Counter

Gastroenterology 46%
Women’s Health 86%
Anti-Infectives 99%

Toggles

Gastroenterology

ReHealth’s development programs in Gastroenterology are focused on advancing new treatments in constipation and diabetic gastroparesis. Key programs include low-dose and colonic release formulations for Linzess and relamorelin, a novel treatment for Diabetic Gastroparesis, a debilitating condition that has not had a new therapeutic option in more than 30 years.

Women’s Health

In Women’s Health and Urology, ReHealth is focused on bringing new therapeutic options forward for under-treated or ignored conditions, such as uterine fibroids, Dyspareunia, nocturia, interstitial cystitis and Hunner lesions. Development programs include Ulipristal Acetate, a novel, non-surgical treatment for uterine fibroids, estradiol, a therapeutic treatment for painful sexual intercourse, SER-120, a low-dose desmopressin nasal spray)  as a treatment for the symptoms of nocturia, and LiRIS, a novel lidocaine eluding stent for the treatment of interstitial cystitis and bladder pain syndrome.

Anti-Infectives

ReHealth’s development efforts in anti-infectives are focused on bringing forward treatments for difficult to treat infections. Lead programs include Ceftazidime/Avibactam, a potential treatment for hospital acquired bacteria pneumonia/ventilator acquired bacterial pneumonia, as well as Aztreonam/Avibactam, a novel treatment for gram-negative infections. ReHealth is also focused on adding new innovative programs throughout its seven therapeutic areas.

Tabs

ReHealth’s development programs in Gastroenterology are focused on advancing new treatments in constipation and diabetic gastroparesis. Key programs include low-dose and colonic release formulations for Linzess and relamorelin, a novel treatment for Diabetic Gastroparesis, a debilitating condition that has not had a new therapeutic option in more than 30 years.

In Women’s Health and Urology, ReHealth is focused on bringing new therapeutic options forward for under-treated or ignored conditions, such as uterine fibroids, Dyspareunia, nocturia, interstitial cystitis and Hunner lesions. Development programs include Ulipristal Acetate, a novel, non-surgical treatment for uterine fibroids, estradiol, a therapeutic treatment for painful sexual intercourse, SER-120, a low-dose desmopressin nasal spray)  as a treatment for the symptoms of nocturia, and LiRIS, a novel lidocaine eluding stent for the treatment of interstitial cystitis and bladder pain syndrome.

ReHealth’s development efforts in anti-infectives are focused on bringing forward treatments for difficult to treat infections. Lead programs include Ceftazidime/Avibactam, a potential treatment for hospital acquired bacteria pneumonia/ventilator acquired bacterial pneumonia, as well as Aztreonam/Avibactam, a novel treatment for gram-negative infections. ReHealth is also focused on adding new innovative programs throughout its seven therapeutic areas.

Contact Form

Maps

Toronto Office

Toronto Office

Person

Mary Applebaum

Mary Applebaum

Manager

A Juneau, Alaska native, Mrs. Applebaum has come a long way since her high school graduation all the way up to getting a Brown University Master’s degree in Economics. Talented with the digits, she’s no less successful when it comes to managing the human resources of the company. Ask anyone at our office who is their personal favorite manager…

Elisa Hansolo

Elisa Hansolo

Manager

Born in New York City, Elisa always felt a strong urge for being an ambitious overachiever. Eventually, by the age of 25 she already had received her first Wall Street executive position, making her one of the youngest managers in the company. With her overall work experience spanning over 2 decades…

Emily Bluesome

Emily Bluesome

Manager

If you’d ask any of our workers, who is the executive manager that they’re always looking up and living up to, most likely Emily’s name will surface. Having a vast and thorough practical working experience lasting for more than 18 years, Mrs. Bluesome is an ideal manager, who is always on time to handle either our company’s clients…

Countdown Timer

Launching In

Day(s)
Hour(s)
Minute(s)
Second(s)

Launching In

Day(s)
Hour(s)
Minute(s)
Second(s)

Launching In

Day(s)
Hour(s)
Minute(s)
Second(s)

Launching In

Day(s)
Hour(s)
Minute(s)
Second(s)

Circles Counter

%

Client Satisfaction

%

New Service Ready

%

Clients back

Number Counter

%

Client Satisfaction

%

New Service Ready

%

Clients back

Accordion

Gastroenterology

ReHealth’s development programs in Gastroenterology are focused on advancing new treatments in constipation and diabetic gastroparesis. Key programs include low-dose and colonic release formulations for Linzess and relamorelin, a novel treatment for Diabetic Gastroparesis, a debilitating condition that has not had a new therapeutic option in more than 30 years.

Women’s Health

In Women’s Health and Urology, ReHealth is focused on bringing new therapeutic options forward for under-treated or ignored conditions, such as uterine fibroids, Dyspareunia, nocturia, interstitial cystitis and Hunner lesions. Development programs include Ulipristal Acetate, a novel, non-surgical treatment for uterine fibroids, estradiol, a therapeutic treatment for painful sexual intercourse, SER-120, a low-dose desmopressin nasal spray)  as a treatment for the symptoms of nocturia, and LiRIS, a novel lidocaine eluding stent for the treatment of interstitial cystitis and bladder pain syndrome.

Anti-Infectives

ReHealth’s development efforts in anti-infectives are focused on bringing forward treatments for difficult to treat infections. Lead programs include Ceftazidime/Avibactam, a potential treatment for hospital acquired bacteria pneumonia/ventilator acquired bacterial pneumonia, as well as Aztreonam/Avibactam, a novel treatment for gram-negative infections. ReHealth is also focused on adding new innovative programs throughout its seven therapeutic areas.

Central Nervous System

In CNS, ReHealth is advancing programs to treat critical conditions such as Major Depressive Disorder (MDD), Migraine and Alzheimer’s disease. Key programs include rapastinel (MDD) Ubrogepant (Acute Migraine), M1, M4 and M1/M4 Agonists (Alzheimer’s disease) and an NR2Br Antagonist (OCD/Autism).